News
5 Biotechnology Stocks to Buy Now
8 May 2013
This week, five Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an ?A? (?strong buy?) or ?B? overall (?buy?). Ariad Pharmaceuticals (NASDAQ:ARIA) is bettering its rating of C (?hold?) from last week to a ...
Click on the link to read the full article at Investorplace.com (This link will open in a new window)7 Biotechnology Stocks to Sell Now
8 May 2013
Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F's in Earnings Growth, Earnings Momentum, and ...
Click on the link to read the full article at Investorplace.com (This link will open in a new window)Teva CEO plans to court Chinese market with generics, respiratory meds
8 May 2013
Teva CEO Jeremy Levin thinks his company and China are a match made in heaven. The Israeli generics giant is, after all, adept at making and selling cheap drugs, which the fast-growing Chinese market needs. And Teva ($TEVA) has a strong portfolio of ...
Click on the link to read the full article at FiercePharma (This link will open in a new window)Genomics, Biotechnology's Oldest Next Big Thing
8 May 2013
The economist Edward Fiedler famously said "He who lives by the crystal ball soon learns to eat ground glass," a statement to whose veracity I can readily attest having written widely on the potential of genomics during my tenure on Wall Street ...
Click on the link to read the full article at FierceBiotech (This link will open in a new window)Raptor Pharmaceutical Licenses IP for Rett Syndrome from French Research ...
8 May 2013
NOVATO, Ca. - Raptor Pharmaceutical Corp. announced in a press release that it has licensed pending patents related to the use of cysteamine for the treatment of Rett syndrome and associated disorders of methyl-CpG binding protein 2 (MECP2).
Click on the link to read the full article at ag-IP-news Agency (This link will open in a new window)ONO PHARMACEUTICAL CO., LTD. : Ono and Dainippon Sumitomo reach ...
8 May 2013
Ono Pharmaceutical Co., Ltd. (Ono, Headquarters: Osaka, Japan; President: Gyo Sagara) and Dainippon Sumitomo Pharma Co., Ltd. (DSP, Headquarters: Osaka, Japan; President: Masayo Tada) announced today that the companies reached an agreement ...
Click on the link to read the full article at 4-traders (press release) (This link will open in a new window)Research and Markets: The Pharmaceutical Market: Malta 2013
8 May 2013
Our in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the ...
Click on the link to read the full article at Business Wire (press release) (This link will open in a new window)Japanese Pharmaceutical Industry Reviewed by GBI Research in In-Demand ...
7 May 2013
Japan's pharmaceutical industry, the world's second largest, was worth USD 89 billion in 2011, representing 10 per cent of the global market share. However, the industry growth has been hindered by biennial drug price cuts in the recent past. Price ...
Click on the link to read the full article at Wall Street Journal (This link will open in a new window)Fear Of The Unknown-A Persistent Challenge For Biotechnology - SpyGhana.com
7 May 2013
The fear that biotechnology crops or genetic modified crops pose adverse health effects without scientific evidence remains a big challenge to adoption and acceptance of the technology which has high ability to addressing global food insecurity. The ...
Click on the link to read the full article at spyghana.com (This link will open in a new window)Portola Pharmaceutical sets targets for $127M IPO
7 May 2013
Drug development startup Portola Pharmaceuticals Inc. set the price range Tuesday for its upcoming initial public offering in which it hopes to raise up to $127 million. The South San Francisco startup led by CEO William Lis said it plans to sell 6.9 ...
Click on the link to read the full article at Silicon Valley Business Journal (This link will open in a new window)
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
